Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports. The firm had revenue of $1.73 million for the quarter, compared to the consensus estimate of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 68.02%. During the same period in the prior year, the business earned ($0.10) earnings per share.
Arbutus Biopharma Price Performance
ABUS stock opened at $3.74 on Friday. The company has a 50 day moving average price of $3.39 and a 200 day moving average price of $2.97. Arbutus Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $3.98. The stock has a market capitalization of $704.87 million, a PE ratio of -8.49 and a beta of 1.96.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the stock. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research note on Thursday, June 6th. JMP Securities increased their target price on Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price target on shares of Arbutus Biopharma in a report on Wednesday, June 5th.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Further Reading
- Five stocks we like better than Arbutus Biopharma
- Bank Stocks – Best Bank Stocks to Invest In
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Technology Stocks Explained: Here’s What to Know About Tech
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Investors Need to Know About Upcoming IPOs
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.